EP0647134A4 - Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure. - Google Patents

Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure.

Info

Publication number
EP0647134A4
EP0647134A4 EP93915448A EP93915448A EP0647134A4 EP 0647134 A4 EP0647134 A4 EP 0647134A4 EP 93915448 A EP93915448 A EP 93915448A EP 93915448 A EP93915448 A EP 93915448A EP 0647134 A4 EP0647134 A4 EP 0647134A4
Authority
EP
European Patent Office
Prior art keywords
conditions
methods
optically pure
compositions used
treat depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93915448A
Other languages
German (de)
English (en)
Other versions
EP0647134A1 (fr
Inventor
James W Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of EP0647134A1 publication Critical patent/EP0647134A1/fr
Publication of EP0647134A4 publication Critical patent/EP0647134A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP93915448A 1992-06-23 1993-06-22 Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure. Withdrawn EP0647134A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90304092A 1992-06-23 1992-06-23
US903040 1992-06-23
PCT/US1993/005966 WO1994000114A1 (fr) 1992-06-23 1993-06-22 Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure

Publications (2)

Publication Number Publication Date
EP0647134A1 EP0647134A1 (fr) 1995-04-12
EP0647134A4 true EP0647134A4 (fr) 1997-07-30

Family

ID=25416838

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93915448A Withdrawn EP0647134A4 (fr) 1992-06-23 1993-06-22 Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure.

Country Status (5)

Country Link
EP (1) EP0647134A4 (fr)
JP (1) JPH08500093A (fr)
AU (1) AU4542893A (fr)
CA (1) CA2138998A1 (fr)
WO (1) WO1994000114A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
GB9402641D0 (en) * 1994-02-11 1994-04-06 Boots Co Plc Therapeutic agents
US5676967A (en) * 1995-04-18 1997-10-14 Brennen Medical, Inc. Mesh matrix wound dressing
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
CA2366660A1 (fr) * 1999-03-19 2000-09-28 Carl M. Mendel Traitement de l'arthrose
CA2368083A1 (fr) 1999-04-06 2000-10-12 Sepracor Inc. Derives de la venlafaxine et leurs procedes de preparation et utilisation
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
EA011451B1 (ru) 2001-02-12 2009-04-28 Уайт Новая соль сукцинат о-десметилвенлафаксина
WO2002083631A1 (fr) 2001-04-13 2002-10-24 Sepracor Inc. Procedes permettant la preparation de didesmethylsibutramine et d'autres derives de sibutramine
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
CN1671368A (zh) * 2002-07-24 2005-09-21 柏树生物科学公司 疼痛继发性抑郁（dsp）的治疗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008993A1 (de) * 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9400114A1 *

Also Published As

Publication number Publication date
EP0647134A1 (fr) 1995-04-12
CA2138998A1 (fr) 1994-01-06
JPH08500093A (ja) 1996-01-09
AU4542893A (en) 1994-01-24
WO1994000114A1 (fr) 1994-01-06

Similar Documents

Publication Publication Date Title
EP0708639A4 (fr) Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (+) optiquement pure
FR15C0089I2 (fr) Antagonistes de recombinaison de l'il-5 utiles dans le traitement des troubles induits par l'il-5
FI933946A7 (fi) Hypoglykeemisinä aineina ja Alzheimerin taudin hoidossa käyttökelpoisia yhdisteitä
FI962557A7 (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
TR199600498A2 (tr) S(+)-ibuprofen'in oral formülasyonlari.
MA23166A1 (fr) Procedes d'utilisation d'hesperetine pour le controle du sebum et le traitement de l'acne .
AR241025A1 (es) Dispersiones de brillo perlino no ionicas, capaces de fluir"
EP0778727A4 (fr) Promoteur vegetal utilise pour diriger l'expression de proteines etrangeres vers l'epiderme de plantes
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
TR26214A (tr) Baryum veya stronsiyum sulfid'in lavgalanma artiklarinin hazirlanmasi.
EP1007036A4 (fr) Procedes mettant en oeuvre un acide butyrique ou des derives d'acide butyrique pour prevenir la perte de cheveux
DE69432706D1 (de) Verfahren zur reinigung von "basic" fibroblasten wachstumsfaktor
DE69519799D1 (de) Verfahren zur herstellung von [s,s]-ethylendiamin-n,n'-dibernsteinsäure
DE69401368D1 (de) Verfahren zur Herstellung von 1,4-Dicyano-2-buten
ITBO950012A0 (it) Integratore liquido per l'arricchimento di concimi e fertilizzanti
FR2757179B1 (fr) Procede de preparation d'amides de l'acide acrylique ou methacrylique
MD145B1 (ro) Bautura de tip brendi "botna"
NO178763C (no) Fremgangsmåte for fremstilling av racemisk og optisk aktiv 1,2,3,4-tetrahydroisochinolin-3-karboksylsyre samt mellomprodukter derav
DE59401800D1 (de) Verfahren zur Herstellung von 1,1'-Binaphthylen
ITTO930806A1 (it) Purificazione dell' 1, 1-dicloro-1-fluoroetano.
EP0979234A4 (fr) Procedes et compositions s'appliquant au diagnostique et au traitement des troubles neuropsychiatriques
EP1052900A4 (fr) Procedes et compositions limitant la croissance de micro-organismes au moyen de bromonitrostyrene et d'acide peracetique
FR2734838B1 (fr) Fragment d'acide nucleique codant pour un enzyme implique dans la voie de biosynthese de l'acide abscisique (aba) chez les plantes
FR2707313B1 (fr) Structure d'ancrage et de liaison amovible et polyvalente pour ossatures pré infrastructures.
CA2217463A1 (fr) Utilisation de la sulbutiamine pour l'obtention de compositions pharmaceutiques utiles dans le traitement de certains troubles psychomoteurs et psycho-intellectuels

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970612

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19991118

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEPRACOR INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050101